SEC Form 10-Q filed by Eledon Pharmaceuticals Inc.
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $9.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $9.00 | Buy | Guggenheim |
| 5/13/2022 | $25.00 → $15.00 | Overweight | Cantor Fitzgerald |
| 11/24/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
Issued on behalf of Avaí Bio, Inc. (OTCQB:AVAI)LAS VEGAS, July 21, 2026 /CNW/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real. The milestone is a supply deal, which may sound unglamorous, but in cell therapy the source of the cells is
Issued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i
ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration ("FDA"). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significant milestone t
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated patients after the first six months post-transplant, compared with seven BPAR events (9.4% of tacrolimus-treated patients) reported in the tacrolimus arm Patient-reported outcomes at 52 weeks favored tegoprubart, with statistically significant improvements versus tacrolimus on two validated measures of symptom burden Conference call and webcast to be held today at 8:00 a.m. ET IRVINE, Calif., Jun
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno